How India Exports Atovaquone to the World

In the United States, the Food and Drug Administration (FDA) oversees the approval and regulation of pharmaceutical products, including Atovaquone. The FDA's Orange Book lists approved Abbreviated New Drug Applications (ANDAs) for generic drugs. As of March 2026, multiple ANDAs for Atovaquone have been approved, indicating a competitive generic market. Recent approvals include those granted in June 2025 and September 2025, reflecting ongoing interest and investment in this therapeutic area.

Regarding import alerts, the FDA issues these to prevent the entry of products that appear to violate regulations. As of March 2026, there are no active import alerts specifically targeting Atovaquone from Indian manufacturers, suggesting compliance with FDA standards. However, it's crucial for exporters to maintain rigorous quality control to avoid potential future alerts. The regulatory pathway for Atovaquone involves submitting an ANDA, demonstrating bioequivalence to the reference listed drug, and adhering to Current Good Manufacturing Practices (CGMP). With 17 active Indian exporters, the competitive landscape necessitates strict compliance with FDA regulations to ensure market access.

In the European Union (EU) and the United Kingdom (UK), Atovaquone requires marketing authorization before it can be sold. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) are responsible for granting these authorizations. As of March 2026, Atovaquone has received marketing authorizations in several EU member states and the UK, indicating its recognized therapeutic value. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines, which ensure that products are consistently produced and controlled according to quality standards. These guidelines are harmonized across the EU and are critical for maintaining product quality and safety.

Atovaquone is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in addressing global health needs. The 24th edition of the list, published in September 2025, features Atovaquone, highlighting its essential role in treating specific infections. Inclusion in this list guides countries in prioritizing procurement and ensuring availability. Additionally, Atovaquone is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which set quality standards for medicines.

In India, Atovaquone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring a doctor's prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) oversees drug pricing, and as of March 2026, Atovaquone is not listed under the Drug Price Control Order (DPCO), meaning it does not have a government-mandated ceiling price. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceuticals; however, Atovaquone is not currently subject to this requirement, facilitating its export process.

The primary patents for Atovaquone have expired, leading to the availability of generic versions in the market. This expiration has intensified competition among manufacturers and exporters, particularly from India, which has become a significant supplier of generic Atovaquone globally. The absence of active patents allows for broader market access and pricing competition, benefiting healthcare systems and patients worldwide.

In May 2025, the NPPA announced a revision of the ceiling prices for several essential medicines; however, Atovaquone was not included in this list, allowing market-driven pricing to continue. In July 2025, the EMA approved a new generic version of Atovaquone, further increasing competition in the European market. In October 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Atovaquone, which may influence national procurement strategies. In December 2025, the CDSCO issued new guidelines for the export of pharmaceuticals, emphasizing the need for stringent quality control measures, which Indian exporters of Atovaquone must adhere to. In February 2026, the FDA conducted inspections of several Indian pharmaceutical manufacturing facilities, including those producing Atovaquone, to ensure compliance with CGMP standards, highlighting the importance of maintaining quality assurance in the export process.

Atovaquone, an antiprotozoal agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70% of India's APIs are imported from China, highlighting a significant vulnerability in the pharmaceutical supply chain.

Recent disruptions have underscored this risk. In February 2025, the U.S. Food and Drug Administration (FDA) issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP). These violations included failures in quality control and facility maintenance, leading to the classification of certain APIs as "adulterated." Such regulatory actions can result in supply interruptions, affecting the availability of essential medications like Atovaquone.

Our proprietary trade data from 2022 to 2026 reveals a high concentration in Atovaquone exports from India. The top five exporters account for 100% of the total export value, with MYLAN LABORATORIES LIMITED alone contributing 94.3% ($934.1M USD). This monopolization poses a significant single-source risk; any operational or compliance issues within this leading exporter could disrupt the global supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-Aminopenicillanic acid (6-APA), essential for various antibiotics. While these initiatives are steps toward reducing import dependence, their impact on Atovaquone's supply chain remains to be seen.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay shipments of APIs and KSMs, leading to production bottlenecks. Additionally, escalating U.S.-China trade tensions have resulted in tariffs and export restrictions, further complicating the procurement of essential raw materials.

Regulatory bodies like the FDA and the European Medicines Agency (EMA) have issued alerts regarding drug shortages stemming from these supply chain vulnerabilities. For instance, in October 2025, the FDA highlighted the risk of shortages due to the U.S.'s heavy reliance on China and India for KSMs, with 58% of KSMs used for U.S.-approved APIs being sole-sourced from a single country. Such dependencies underscore the need for diversified sourcing strategies to ensure a stable supply of medications like Atovaquone.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce reliance on a single source.

• Enhance Domestic Production: Invest in local manufacturing capabilities for APIs and KSMs to decrease dependency on imports, leveraging government incentives like the PLI scheme.

• Strengthen Quality Assurance: Implement rigorous quality control measures to ensure compliance with international standards, minimizing the risk of regulatory actions that could disrupt supply.

• Develop Contingency Plans: Establish robust risk management strategies, including maintaining buffer stocks and identifying alternative shipping routes to mitigate potential disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact the pharmaceutical supply chain, allowing for proactive adjustments.

RISK_LEVEL: HIGH